Log in
CHEST

CTS 2023 guideline: pharmacotherapy for stable COPD

This Canadian Thoracic Society guideline addresses maintenance pharmacotherapy choices for patients with stable COPD, focusing on initial and follow-up treatment with bronchodilators, inhaled corticosteroids, and other agents. The overall message is to match therapy intensity to symptom burden and exacerbation risk, favoring combination bronchodilator therapy over monotherapy in most symptomatic patients and reserving inhaled corticosteroid-containing regimens for those with frequent exacerbations and higher eosinophil counts.

CHEST2023 editionSummary
Official guideline2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD. CHEST, 2023.
Read the official guideline · Checked for a newer edition on 2026-10-20
We do not reproduce the guideline text — this page is an independent summary.

Who it applies to

Adults with stable, clinically diagnosed COPD being managed in outpatient and primary care settings, excluding acute exacerbation management.

Key recommendations

  • Long-acting bronchodilator therapy (LABA or LAMA) is recommended over short-acting agents alone for patients with persistent symptoms.
  • Combination LABA/LAMA therapy is preferred over either agent alone for most patients with significant dyspnea or activity limitation.
  • Inhaled corticosteroids should not be used as monotherapy in COPD.
  • Triple therapy (LABA/LAMA/ICS) is recommended for patients with continued exacerbations despite LABA/LAMA therapy, particularly those with higher blood eosinophil counts.
  • Blood eosinophil count is highlighted as a biomarker to help predict responsiveness to inhaled corticosteroids.
  • Routine use of inhaled corticosteroids is discouraged in patients with a history of pneumonia or low eosinophil counts due to unfavorable risk-benefit balance.
  • Roflumilast or macrolide maintenance therapy may be considered as add-on options in select patients with frequent exacerbations despite optimized inhaled therapy.
  • Treatment escalation and de-escalation should be guided by ongoing reassessment of symptoms and exacerbation frequency rather than spirometric severity alone.

What is new in this edition

  • Greater emphasis on blood eosinophil count as a decision tool for initiating or withdrawing inhaled corticosteroids compared with earlier Canadian guidance.
  • Clearer positioning of LABA/LAMA combination therapy as a preferred initial option over monotherapy for symptomatic patients.

Practice points for students

  • Avoid starting inhaled corticosteroids in COPD patients without a clear exacerbation-prone phenotype, especially if eosinophils are low, due to pneumonia risk.
  • Think of triple therapy as reserved for exacerbation-prone patients, not as a default step-up for dyspnea alone.
  • Reassess inhaler technique and adherence before escalating therapy.
  • Blood eosinophil count is a practical, low-cost biomarker exam questions may use to test ICS decision-making in COPD.

Condition

Chronic obstructive pulmonary disease

Other guidelines on this topic

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by CHEST. It is not medical advice: always read the original guideline before applying it to patients.